十年影像学变化轨迹:银屑病关节炎患者从传统合成改善病情抗风湿药转向抗肿瘤坏死因子治疗的影响
该回顾性研究取自Bath纵向队列,纳入28例银屑病关节炎患者,分析启动抗TNF治疗前5年、启动时及启动后5年的手足X线片。结果显示,启动抗TNF后mSvdHS年变化率中位数从2.1降至1.0(P=0.012),总体影像学损伤累积轨迹较低。
要点
- 启动抗TNF后mSvdHS年变化率中位数由2.1降至1.0(P=0.012)。
- 基线mSvdHS中位数为8.5(IQR 1.75-27.5)。
- 十年观察期内总体影像学损伤累积轨迹较低。
核心结论
- 在该观察性临床队列中,十年期间影像学损伤累积轨迹总体较低。
- 以mSvdHS衡量的影像学损伤速率在启动抗TNF后减慢。
研究设计与样本
- 回顾性样本取自Bath纵向队列,纳入28例符合银屑病关节炎分类标准(ClASsification criteria for Psoriatic ARthritis)的患者。
- 所有患者均有手和足X线片:启动抗TNF前5年(T0)、启动时(T1)及启动后5年(T2)。
- X线片由A.Allard、A.Antony和W.T.盲法评分,采用银屑病关节炎改良Sharp-van der Heijde评分(mSvdHS)和骨增殖评分(Psoriatic Arthritis Ratingen Score)。
- 样本量计算旨在确保以5%显著性水平检测mSvdHS最小可检测差异时具有90%把握度。
- 采用累积概率图确定抗TNF治疗前(T0-T1)和治疗后(T1-T2)影像学进展的概率。
主要发现
- 共选取28例患者的84张X线片纳入分析。
- 基线(T0)中位病程为8.5(0-19.5)年。
- T0-T1间隔为4.2年(3.34-6.65),T1-T2间隔为4.9年(4.25-5.87)。
- 基线(T0)mSvdHS中位数为8.5(IQR 1.75-27.5)。
- mSvdHS年变化率中位数在启动抗TNF后由T0-T1的2.1(0.88-3.92)降至T1-T2的1.0(IQR 0.05-2.35)(P=0.012)。
关键数值与推荐
- mSvdHS年变化率中位数:T0-T1为2.1(0.88-3.92),T1-T2为1.0(IQR 0.05-2.35),启动抗TNF后降低(P=0.012)。
- 基线(T0)mSvdHS中位数为8.5(IQR 1.75-27.5)。
- 基线(T0)中位病程为8.5(0-19.5)年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the trajectory of radiographic progression among patients with PsA who transitioned from conventional synthetic DMARDs to anti-TNF-α inhibitors in routine care. METHODS: A retrospective sample of patients with PsA (ClASsification criteria for Psoriatic ARthritis) was taken from the Bath longitudinal cohort. All patients had radiographs of the hands and feet taken: 5 years before (T0), at the time of (T1) and 5 years after (T2) commencing anti-TNF treatment. Radiographs were scored blinded using the PsA-modified Sharp-van der Heijde score (mSvdHS) and for osteoproliferation (Psoriatic Arthritis Ratingen Score) by A.Allard, A.Antony and W.T. This sample size was calculated to ensure 90% power to determine the smallest detectable difference of the mSvdHS to a 5% significance level. Cumulative probability plots were used to determine the probability of radiographic progression pre- (T0-T1) and post- (T1-T2) anti-TNF treatment. RESULTS: Eighty-four radiographs from 28 patients were selected for inclusion. The median [interquartile range (IQR)] disease duration at baseline (T0) was 8.5 (0-19.5) years. The interval between T0-T1 and T1-T2 was 4.2 years (3.34-6.65) and 4.9 years (4.25-5.87), respectively. The median mSvdHS at baseline (T0) was 8.5 (IQR 1.75-27.5). The median (IQR) rate of change in mSvdHS per year reduced after commencing anti-TNF, from 2.1 (0.88-3.92) between T0-T1 to 1.0 (IQR 0.05-2.35) between T1-T2 (P = 0.012). CONCLUSION: The trajectory of damage accumulation over a 10-year period in this observational clinical cohort is low overall. The rate of radiographic damage as measured by the mSvdHS slows following commencement of anti-TNF.
引用
- Allard A, Antony A, Shaddick G, et al. Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis. Rheumatology (Oxford). 2019. PMID: 30247726. doi:10.1093/rheumatology/key297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。